Background: Diabetes mellitus and hypertension are the leading causes of cardiovascular disease in the renal transplant recipients. This review looks at the potential role of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and reviews the management strategies for hypertension in this population.
Summary: Large-scale clinical trials are needed to study the potential cardiorenal benefits and risks of complications in renal transplant recipients. Future clinical trials are also needed to define optimal blood pressure treatment goals and therapies and how they influence graft and patient survival.
Key Messages: Multiple recent prospective randomized clinical trials have shown the benefits of using SGLT2is to improve the cardiorenal outcomes in patients with chronic kidney disease with or without diabetes mellitus. Renal transplant recipients were not included in these trials due to concerns about genitourinary complications; hence, the role of these agents in this population is unclear. A number of small studies have highlighted the safety of using these agents in renal transplant recipients. Posttransplant hypertension is a complex problem requiring individualized management. Recent guidelines recommend using a calcium channel blocker or angiotensin receptor blocker as the first-line antihypertensive agents in adult renal transplant recipients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000530296 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Depression and anxiety in people with kidney disease: understanding symptom variability, patient experience and preferences for mental health support.
J Nephrol
January 2025
School of Life and Medical Sciences, University of Hertfordshire, College Lane Campus, Hatfield, UK.
Article Synopsis
- The study investigates the prevalence and factors related to depression and anxiety among individuals with chronic kidney disease (CKD) in the UK, revealing that significant portions experience these mental health issues.
- Participants completed an online survey that assessed mental health history and treatment preferences, finding that over half had a history of diagnosed depression and many preferred in-person support.
- The results indicated that certain demographics, including age and gender, as well as factors like self-efficacy and current treatment, were significantly related to the levels of depression and anxiety symptoms, but differences in symptoms were not influenced by the kidney service centers’ location or size.
The Future of Glucagon-Like Peptide-1 Receptor Agonists In Cardiovascular-Kidney-Metabolic Diseases.
Nephrol Dial Transplant
January 2025
Department of Nephrology, Hospital Universitario 12 de Octubre.
Unveiling the risks: protecting privacy in single-cell genomics data.
Nephrol Dial Transplant
January 2025
Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.
Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study.
BMC Nephrol
January 2025
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Key Laboratory of Organ Transplantation, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Huazhong University of Science and Technology, Ministry of Education, Chinese Academy of Medical Sciences, Wuhan, China.
Background: Effective treatment of late antibody-mediated rejection (late AMR) is still an unmet medical need. Clearing donor-specific antibody (DSA) and preventing its rebound is the ideal goal of treatment.
Methods: We have summarized the clinical data from seven patients with late or chronic active AMR after renal transplantation who received daratumumab (Dara)-based treatment first (Phase 1) and then tocilizumab (TCZ) therapy (Phase 2).
Serosurvey of Visceral Leishmaniasis in Organ Transplant Recipients in the South of Iran.
Transplant Proc
January 2025
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
Background: Visceral leishmaniasis (VL) can become active and cause specific problems in transplant recipients. The current study was conducted with the aim of serological evaluation of VL in transplant patients in a comprehensive transplantation center in Fars province southern Iran.
Methods: The study population included 150 organ transplant recipients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!